Chemical formula: C₂₁H₂₅ClN₆O₂ Molecular mass: 428.173 g/mol PubChem compound: 25227436
Capivasertib is indicated for:
Population group: only adults (18 years old or older)
Capivasertib is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen.
In pre- or perimenopausal women, capivasertib plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist.
For men, administration of LHRH agonist according to current clinical practice standards should be considered.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Capivasertib is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
